What is HC Wainwright's Estimate for Invivyd Q2 Earnings?

Invivyd, Inc. (NASDAQ:IVVD - Free Report) - Analysts at HC Wainwright decreased their Q2 2025 earnings per share (EPS) estimates for shares of Invivyd in a research report issued on Wednesday, May 28th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($0.02) per share for the quarter, down from their prior estimate of $0.02. HC Wainwright has a "Buy" rating and a $5.00 price objective on the stock. The consensus estimate for Invivyd's current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Invivyd's Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.17) EPS, FY2026 earnings at $0.08 EPS, FY2027 earnings at $0.16 EPS and FY2029 earnings at $0.27 EPS.

Separately, D. Boral Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Invivyd in a report on Friday, May 16th.

Invivyd Stock Performance

Invivyd stock traded up $0.09 during midday trading on Friday, reaching $1.02. The stock had a trading volume of 1,277,037 shares, compared to its average volume of 4,489,949. Invivyd has a twelve month low of $0.35 and a twelve month high of $2.74. The stock has a market capitalization of $122.36 million, a PE ratio of -0.52 and a beta of 0.40. The stock's 50-day simple moving average is $0.65 and its 200 day simple moving average is $0.74.

Invivyd (NASDAQ:IVVD - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.10). The company had revenue of $11.30 million during the quarter, compared to analysts' expectations of $34.45 million.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC raised its position in Invivyd by 2,051.0% in the first quarter. AQR Capital Management LLC now owns 410,711 shares of the company's stock valued at $249,000 after purchasing an additional 391,617 shares during the period. Nuveen LLC purchased a new position in Invivyd in the first quarter valued at about $65,000. Invesco Ltd. raised its position in Invivyd by 190.6% in the first quarter. Invesco Ltd. now owns 108,999 shares of the company's stock valued at $66,000 after purchasing an additional 71,485 shares during the period. XTX Topco Ltd purchased a new position in Invivyd in the first quarter valued at about $66,000. Finally, Two Sigma Investments LP increased its position in shares of Invivyd by 125.3% during the fourth quarter. Two Sigma Investments LP now owns 367,100 shares of the company's stock worth $163,000 after acquiring an additional 204,188 shares during the last quarter. 70.36% of the stock is owned by hedge funds and other institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.